{"title":"关于内镜超声造影治疗胰腺癌疗效的荟萃分析","authors":"Min Xuan, Na Li, Chunyan Wu","doi":"10.1016/j.clinsp.2024.100348","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to systematically evaluate the efficacy and safety of Endoscopic Ultrasonography (EUS) for the treatment of pancreatic cancer.</p></div><div><h3>Methods</h3><p>The PubMed, Embase, Web of Science, and Google Scholar databases were searched from the inception of the databases to June 2022. RevMan 5.3.0 software was utilized for data analysis. In total, 13 self-descriptive studies, which enrolled 382 patients, were finally included.</p></div><div><h3>Results</h3><p>It was revealed that EUS for the treatment of pancreatic cancer exhibited a lower incidence of adverse reactions (Relative Risk Ration [RR = 0.23], 95 % Confidence interval [95 % CI 0.23–0.23]), a higher success rate (RR = 0.90, 95 % CI 0.90–0.90), and a low failure rate (RR = 0.06, 95 % CI 0.06–0.06). Moreover, EUS-guided Celiac Plexus Neurolysis (EUS-CPN) not only significantly relieved pancreatic cancer patients’ pain (RR = 0.83, 95 % CI 0.83–0.83), but also significantly eliminated pain in some patients (RR = 0.09, 95 % CI 0.09–0.09). The effects of EUS on pancreatic cancer treatment were satisfactory, and few adverse reactions were found.</p></div><div><h3>Conclusion</h3><p>Owing to the restricted sample size in this meta-analysis, primarily consisting of descriptive studies, it was imperative to conduct more rigorously designed, multi-center, long-term follow-up, larger sample, and Randomized Controlled Trials (RCTs) to validate the findings.</p></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1807593224000255/pdfft?md5=af25fcba895a6132a5d2dad07bb20036&pid=1-s2.0-S1807593224000255-main.pdf","citationCount":"0","resultStr":"{\"title\":\"A meta-analysis on the efficacy of endoscopic ultrasonography for treatment of pancreatic cancer\",\"authors\":\"Min Xuan, Na Li, Chunyan Wu\",\"doi\":\"10.1016/j.clinsp.2024.100348\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>This study aimed to systematically evaluate the efficacy and safety of Endoscopic Ultrasonography (EUS) for the treatment of pancreatic cancer.</p></div><div><h3>Methods</h3><p>The PubMed, Embase, Web of Science, and Google Scholar databases were searched from the inception of the databases to June 2022. RevMan 5.3.0 software was utilized for data analysis. In total, 13 self-descriptive studies, which enrolled 382 patients, were finally included.</p></div><div><h3>Results</h3><p>It was revealed that EUS for the treatment of pancreatic cancer exhibited a lower incidence of adverse reactions (Relative Risk Ration [RR = 0.23], 95 % Confidence interval [95 % CI 0.23–0.23]), a higher success rate (RR = 0.90, 95 % CI 0.90–0.90), and a low failure rate (RR = 0.06, 95 % CI 0.06–0.06). Moreover, EUS-guided Celiac Plexus Neurolysis (EUS-CPN) not only significantly relieved pancreatic cancer patients’ pain (RR = 0.83, 95 % CI 0.83–0.83), but also significantly eliminated pain in some patients (RR = 0.09, 95 % CI 0.09–0.09). The effects of EUS on pancreatic cancer treatment were satisfactory, and few adverse reactions were found.</p></div><div><h3>Conclusion</h3><p>Owing to the restricted sample size in this meta-analysis, primarily consisting of descriptive studies, it was imperative to conduct more rigorously designed, multi-center, long-term follow-up, larger sample, and Randomized Controlled Trials (RCTs) to validate the findings.</p></div>\",\"PeriodicalId\":10472,\"journal\":{\"name\":\"Clinics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1807593224000255/pdfft?md5=af25fcba895a6132a5d2dad07bb20036&pid=1-s2.0-S1807593224000255-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1807593224000255\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1807593224000255","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
方法检索PubMed、Embase、Web of Science和Google Scholar数据库,检索时间从数据库建立之初至2022年6月。使用RevMan 5.3.0软件进行数据分析。结果显示,EUS 治疗胰腺癌的不良反应发生率较低(相对风险系数 [RR = 0.23],95 % 置信区间 [95 % CI 0.23-0.23]),成功率较高(RR = 0.90,95 % CI 0.90-0.90),失败率较低(RR = 0.06,95 % CI 0.06-0.06)。此外,EUS引导下的腹腔神经丛神经切断术(EUS-CPN)不仅能显著缓解胰腺癌患者的疼痛(RR = 0.83,95 % CI 0.83-0.83),还能明显消除部分患者的疼痛(RR = 0.09,95 % CI 0.09-0.09)。结论由于该荟萃分析的样本量有限,且主要由描述性研究组成,因此必须开展设计更严谨、多中心、长期随访、样本量更大的随机对照试验(RCT)来验证研究结果。
A meta-analysis on the efficacy of endoscopic ultrasonography for treatment of pancreatic cancer
Objective
This study aimed to systematically evaluate the efficacy and safety of Endoscopic Ultrasonography (EUS) for the treatment of pancreatic cancer.
Methods
The PubMed, Embase, Web of Science, and Google Scholar databases were searched from the inception of the databases to June 2022. RevMan 5.3.0 software was utilized for data analysis. In total, 13 self-descriptive studies, which enrolled 382 patients, were finally included.
Results
It was revealed that EUS for the treatment of pancreatic cancer exhibited a lower incidence of adverse reactions (Relative Risk Ration [RR = 0.23], 95 % Confidence interval [95 % CI 0.23–0.23]), a higher success rate (RR = 0.90, 95 % CI 0.90–0.90), and a low failure rate (RR = 0.06, 95 % CI 0.06–0.06). Moreover, EUS-guided Celiac Plexus Neurolysis (EUS-CPN) not only significantly relieved pancreatic cancer patients’ pain (RR = 0.83, 95 % CI 0.83–0.83), but also significantly eliminated pain in some patients (RR = 0.09, 95 % CI 0.09–0.09). The effects of EUS on pancreatic cancer treatment were satisfactory, and few adverse reactions were found.
Conclusion
Owing to the restricted sample size in this meta-analysis, primarily consisting of descriptive studies, it was imperative to conduct more rigorously designed, multi-center, long-term follow-up, larger sample, and Randomized Controlled Trials (RCTs) to validate the findings.
期刊介绍:
CLINICS is an electronic journal that publishes peer-reviewed articles in continuous flow, of interest to clinicians and researchers in the medical sciences. CLINICS complies with the policies of funding agencies which request or require deposition of the published articles that they fund into publicly available databases. CLINICS supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration.